Abstract

Blood cell-derived microparticles (MP), in general, and platelet MPs (PMPs), in particular, have emerged as important contributors, as well as markers, of the delicate balance between health and disease. They may, on one hand, have beneficial effects by supporting tissue repair and regeneration, as well as hemostasis, but may, on the other hand, be a pro-coagulant promoter leading to the thrombotic events seen in the context of cancer. PMPs can act as a direct tumor growth enhancer through the release of potent growth factors in the tumor micro-environment. Tumor engraftment can also be stimulated by the pro-angiogenic potentials of platelet growth factors released by PMPs. PMPs, by their pro-inflammatory and immunomodulatory functions, can also exert an indirect role in the metastatic multistep process by helping malignant cells to escape from immunological surveillance. The possible detrimental effect of transfusions in cancer patients has been debated for several years and the role played by PMPs present in blood products is receiving specific attention, considering their propensity to trigger thrombosis and support tumors. The intimate PMP-tumors crosstalk may therefore result in pro-thrombotic states and a physiological state favorable to tumor growth, tethering and dissemination. Laboratory and experimental studies are needed to better unveil the contribution of PMPs as coagulation promoters, as well as potential markers and targets to treat cancer.

Original languageEnglish
Pages (from-to)168-172
Number of pages5
JournalTransfusion and Apheresis Science
Volume53
Issue number2
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Blood Platelets
Neoplasms
Intercellular Signaling Peptides and Proteins
Cell-Derived Microparticles
Immunologic Surveillance
Coagulants
Growth
Hemostasis
Regeneration
Blood Cells
Thrombosis
Health

ASJC Scopus subject areas

  • Hematology

Cite this

Platelet microparticles and cancer : An intimate cross-talk. / Goubran, Hadi; Sabry, Waleed; Kotb, Rami; Seghatchian, Jerard; Burnouf, Thierry.

In: Transfusion and Apheresis Science, Vol. 53, No. 2, 01.10.2015, p. 168-172.

Research output: Contribution to journalReview article

Goubran, Hadi ; Sabry, Waleed ; Kotb, Rami ; Seghatchian, Jerard ; Burnouf, Thierry. / Platelet microparticles and cancer : An intimate cross-talk. In: Transfusion and Apheresis Science. 2015 ; Vol. 53, No. 2. pp. 168-172.
@article{f08e004d05b647d4af7553ab8ea43d37,
title = "Platelet microparticles and cancer: An intimate cross-talk",
abstract = "Blood cell-derived microparticles (MP), in general, and platelet MPs (PMPs), in particular, have emerged as important contributors, as well as markers, of the delicate balance between health and disease. They may, on one hand, have beneficial effects by supporting tissue repair and regeneration, as well as hemostasis, but may, on the other hand, be a pro-coagulant promoter leading to the thrombotic events seen in the context of cancer. PMPs can act as a direct tumor growth enhancer through the release of potent growth factors in the tumor micro-environment. Tumor engraftment can also be stimulated by the pro-angiogenic potentials of platelet growth factors released by PMPs. PMPs, by their pro-inflammatory and immunomodulatory functions, can also exert an indirect role in the metastatic multistep process by helping malignant cells to escape from immunological surveillance. The possible detrimental effect of transfusions in cancer patients has been debated for several years and the role played by PMPs present in blood products is receiving specific attention, considering their propensity to trigger thrombosis and support tumors. The intimate PMP-tumors crosstalk may therefore result in pro-thrombotic states and a physiological state favorable to tumor growth, tethering and dissemination. Laboratory and experimental studies are needed to better unveil the contribution of PMPs as coagulation promoters, as well as potential markers and targets to treat cancer.",
author = "Hadi Goubran and Waleed Sabry and Rami Kotb and Jerard Seghatchian and Thierry Burnouf",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.transci.2015.10.014",
language = "English",
volume = "53",
pages = "168--172",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Platelet microparticles and cancer

T2 - An intimate cross-talk

AU - Goubran, Hadi

AU - Sabry, Waleed

AU - Kotb, Rami

AU - Seghatchian, Jerard

AU - Burnouf, Thierry

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Blood cell-derived microparticles (MP), in general, and platelet MPs (PMPs), in particular, have emerged as important contributors, as well as markers, of the delicate balance between health and disease. They may, on one hand, have beneficial effects by supporting tissue repair and regeneration, as well as hemostasis, but may, on the other hand, be a pro-coagulant promoter leading to the thrombotic events seen in the context of cancer. PMPs can act as a direct tumor growth enhancer through the release of potent growth factors in the tumor micro-environment. Tumor engraftment can also be stimulated by the pro-angiogenic potentials of platelet growth factors released by PMPs. PMPs, by their pro-inflammatory and immunomodulatory functions, can also exert an indirect role in the metastatic multistep process by helping malignant cells to escape from immunological surveillance. The possible detrimental effect of transfusions in cancer patients has been debated for several years and the role played by PMPs present in blood products is receiving specific attention, considering their propensity to trigger thrombosis and support tumors. The intimate PMP-tumors crosstalk may therefore result in pro-thrombotic states and a physiological state favorable to tumor growth, tethering and dissemination. Laboratory and experimental studies are needed to better unveil the contribution of PMPs as coagulation promoters, as well as potential markers and targets to treat cancer.

AB - Blood cell-derived microparticles (MP), in general, and platelet MPs (PMPs), in particular, have emerged as important contributors, as well as markers, of the delicate balance between health and disease. They may, on one hand, have beneficial effects by supporting tissue repair and regeneration, as well as hemostasis, but may, on the other hand, be a pro-coagulant promoter leading to the thrombotic events seen in the context of cancer. PMPs can act as a direct tumor growth enhancer through the release of potent growth factors in the tumor micro-environment. Tumor engraftment can also be stimulated by the pro-angiogenic potentials of platelet growth factors released by PMPs. PMPs, by their pro-inflammatory and immunomodulatory functions, can also exert an indirect role in the metastatic multistep process by helping malignant cells to escape from immunological surveillance. The possible detrimental effect of transfusions in cancer patients has been debated for several years and the role played by PMPs present in blood products is receiving specific attention, considering their propensity to trigger thrombosis and support tumors. The intimate PMP-tumors crosstalk may therefore result in pro-thrombotic states and a physiological state favorable to tumor growth, tethering and dissemination. Laboratory and experimental studies are needed to better unveil the contribution of PMPs as coagulation promoters, as well as potential markers and targets to treat cancer.

UR - http://www.scopus.com/inward/record.url?scp=84951790216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951790216&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2015.10.014

DO - 10.1016/j.transci.2015.10.014

M3 - Review article

C2 - 26542350

AN - SCOPUS:84951790216

VL - 53

SP - 168

EP - 172

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 2

ER -